Cancer Chemotherapy and Biotherapy : (Record no. 49913)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 04733nam a22004933i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC2031972 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240729123552.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2010 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781469874821 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781605474311 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC2031972 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL2031972 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (CaPaEBR)ebr10824498 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)686682029 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC271.C5 -- C32219 2011eb |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.99/4061 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Chabner, Bruce A. |
| 245 10 - TITLE STATEMENT | |
| Title | Cancer Chemotherapy and Biotherapy : |
| Remainder of title | Principles and Practice. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 5th ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Philadelphia : |
| Name of producer, publisher, distributor, manufacturer | Wolters Kluwer Health, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2010. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2011. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (836 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cancer Chemotherapy and Biotherapy: Principles and Practice -- CONTENTS -- PREFACE -- ACKNOWLEDGMENTS -- CONTRIBUTORS -- Section I Basic Principles of Cancer Treatment -- Clinical Strategies for Cancer Treatment: The Role of Drugs -- Target Identifi cation and Drug Discovery -- Clinical Drug Development and Marketing Approval -- Principles of Pharmacokinetics -- Delivering Anticancer Drugs to Brain Tumors -- Pharmacogenetics -- Physical Barriers to Drug Delivery -- Section II Cytotoxic Agents -- Antifolates -- 5-Fluoropyrimidines -- Cytidine Analogues -- Purine Antimetabolites -- Hydroxyurea -- Antimitotic Drugs -- Alkylating Agents -- Platinum Analogues -- Bleomycin and Other Antitumor Antibiotics -- Topoisomerase I-Targeting Drugs -- Topoisomerase II Inhibitors: Anthracyclines -- Topoisomerase II Inhibitors: The Epipodophyllotoxins -- Asparaginase -- Section III Molecularly Targeted Therapies -- Proteasome Inhibitors -- Histone Deacetylase Inhibitors in Oncology -- Differentiating Agents -- Arsenic Trioxide -- Antibodies -- Inhibitors of Tumor Angiogenesis -- Epidermal Growth Factor Receptor Inhibitors -- HER2 Inhibitors -- Molecular Targeted Drugs -- Signaling Inhibitors: IGFR, PI3K Pathway, Embryonic Signaling Inhibitors, and Mitotic Kinase Inhibitors -- Section IV Immunologic Agents -- Cytokine Therapy for Cancer -- Cancer Vaccines -- Adoptive Cellular Therapies -- Thalidomide and Its Analogs in the Treatment of Hematologic Malignancies, Including Multiple Myeloma, and Solid Tumors -- Section V Hormonal Therapy -- Hormonal Therapy of Breast Cancer -- Hormone Therapy for Prostate Cancer -- Section VI Supportive Care -- Drug Therapy of Pain in Cancer Patients -- Hematopoietic Growth Factors -- Antinausea Medications -- Bisphosphonates and Other Bone-Targeted Therapies -- Intravenous Access and Catheter Management -- Section VII Survivorship. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Late Effects of Cancer Chemotherapy -- Infertility After Cancer Chemotherapy -- INDEX. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Updated to include the newest drugs and those currently in development, this Fifth Edition is a comprehensive reference on the preclinical and clinical pharmacology of anticancer agents. Organized by drug class, the book provides the latest information on all drugs and biological agents-their mechanisms of action, interactions with other agents, toxicities, side effects, and mechanisms of resistance. The authors explain the rationale for use of drugs in specific schedules and combinations and offer guidelines for dose adjustment in particular situations. This edition's introduction includes timely information on general strategies for drug usage, the science of drug discovery and development, economic and regulatory aspects of cancer drug development, and principles of pharmacokinetics. Eight new chapters have been added and more than twenty have been significantly revised. A companion website includes the fully searchable text and an image bank. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cancer -- Chemotherapy. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Cancer -- Immunotherapy. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Antineoplastic agents. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Biological response modifiers. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Longo, Dan L. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Chabner, Bruce A. |
| Title | Cancer Chemotherapy and Biotherapy |
| Place, publisher, and date of publication | Philadelphia : Wolters Kluwer Health,c2010 |
| International Standard Book Number | 9781605474311 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=2031972">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=2031972</a> |
| Public note | Click to View |
No items available.